Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1862 results
November 2015
-
Press Release
Novartis presents new two year data for Cosentyx® showing no progression in joint damage in 84% of psoriatic arthritis patients
New x-ray assessment data, from a sub-study, showed no progression of joint structural damage in the majority of patients with psoriatic arthritis over two years[1] Psoriatic arthritis patients on… -
Press Release
New two year data for Novartis' Cosentyx® show sustained response and no progression in spinal damage as shown by x-ray in up to 80% of patients with ankylosing spondylitis
A sub-study showed up to 80% of ankylosing spondylitis (AS) patients treated with Cosentyx had no radiographic progression in the spine over two years[1] Cosentyx demonstrated a sustained… -
Story From Our Labs
Giraffes have high blood pressure. Why don’t they drop dead?
A certain leggy resident of the African grasslands is arousing a lot of interest among evolutionary biologists. They believe that study of giraffes' unique features could lead the way to advances in human health.
-
Press Release
Novartis nominating Elizabeth Doherty and Ton Buechner to the Board of Directors
Nominees for election by shareholders at Annual General Meeting (AGM) in February 2016 Basel, November 4, 2015 - The Novartis Board of Directors announced today, that it is nominating Ms.…
October 2015
-
Press Release
Novartis Foundation and partners launch new hypertension program in Ghana
Community-based Hypertension Improvement Project (ComHIP) is an innovative healthcare model designed to improve hypertension management and control Screening and treatment is shifted to the… -
Story Discovery
Stepping toward regenerative medicine for diabetes
Discovery points toward treatment options beyond insulin injections
-
Story Discovery
Compounds spur insulin-producing cells to replicate in the lab
-
Press Release
Novartis a réalisé, au troisième trimestre, une forte hausse de sa marge core (tcc) et continué de renforcer son pipeline, confirmant ainsi ses prévisions pour l'exercice
Croissance solide (tcc[1]), au T3, des ventes, du résultat opérationnel core et du BPA core des activités poursuivies[2] Chiffre d'affaires net d'USD 12,3 milliards (-6%, +6% tcc) Résultat… -
Press Release
Novartis steigert die Kerngewinnmarge (kWk) im dritten Quartal kräftig, stärkt erneut die Pipeline und ist auf Kurs für die Jahresprognose
Solides Wachstum (kWk[1]) im dritten Quartal beim Umsatz, operativen Kernergebnis und Kerngewinn pro Aktie der fortzuführenden Geschäftsbereiche[2]: Der Nettoumsatz beläuft sich auf USD 12,3… -
Press Release
Novartis delivered strong core margin expansion (cc) and continued to strengthen the pipeline in Q3; on track for full-year guidance
Solid growth (cc[1]) in Q3 sales, core operating income, core EPS for continuing operations[2] Net sales were USD 12.3 billion (-6%, +6% cc) Operating income was USD 2.2 billion (-18%, +2% cc) Core… -
Press Release
Novartis receives positive CHMP opinion for the first IL-17A inhibitor Cosentyx(TM) to treat ankylosing spondylitis and psoriatic arthritis
Cosentyx (secukinumab) is recommended for approval in Europe for the treatment of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients Cosentyx demonstrated rapid onset of… -
Press Release
Novartis broadens immuno-oncology pipeline with acquisition of Admune Therapeutics and licensing agreements with XOMA and Palobiofarma
With four programs currently in clinical trials and five more expected to enter the clinic by the end of 2016, Novartis has rapidly built a robust portfolio of programs focused on stimulating the…